Subretinal Fluid and Pigment Epithelial Detachment in AMD
What Subretinal Fluid and PED Are
Subretinal fluid (SRF) is a layer of fluid that collects between your retina and the retinal pigment epithelium (RPE) beneath it. In age-related macular degeneration (AMD), this fluid can leak from abnormal blood vessels that have grown under the retina. SRF pushes the retina upward, distorting your vision and damaging the photoreceptors that give you sharp central sight.
Your doctor detects subretinal fluid using optical coherence tomography (OCT), which shows a dark (hyporeflective) space between the retina and RPE on cross-section images. Even small amounts of SRF can affect your visual acuity if they involve the fovea, the very center of your macula.
Pigment epithelial detachment (PED) occurs when the RPE layer separates from Bruch's membrane beneath it. The space between them fills with fluid, blood, or fibrovascular tissue depending on the type of PED. According to StatPearls and PMC, PEDs in AMD are classified into four main types, each with distinct imaging features and clinical implications.
PEDs appear on OCT as dome-shaped elevations of the RPE line. Your doctor identifies the type of PED based on what fills the space beneath the elevated RPE. This classification helps determine whether the PED is a passive drusen-related change or a sign of active neovascular disease.
The presence of subretinal fluid or a PED tells your doctor that fluid is accumulating where it should not be. In wet AMD, this fluid comes from leaking choroidal neovascularization (CNV). In dry AMD, drusenoid PEDs form from the coalescence of drusen deposits. Your doctor uses these findings to decide whether treatment is needed and which type of treatment will work best.
Monitoring SRF and PED size at each visit helps your doctor assess whether your AMD is stable or progressing. Changes in fluid volume or PED shape can prompt a change in treatment or a switch to a different anti-VEGF medication.
Types of Pigment Epithelial Detachment
Drusenoid PEDs form when soft drusen merge and lift the RPE away from Bruch's membrane. According to PMC, they display a homogenous, slightly bright (hyperreflective) interior on OCT. Drusenoid PEDs are a marker of intermediate AMD progression risk.
These PEDs do not involve abnormal blood vessels or active fluid leakage. Your doctor monitors them over time because they can evolve into geographic atrophy as the RPE above the drusen material fails. A drusenoid PED does not require anti-VEGF treatment.
Fibrovascular PEDs are associated with Type 1 choroidal neovascularization, where abnormal blood vessels grow beneath the RPE. On OCT, they appear as irregular RPE elevations with a mixed-brightness, non-uniform interior. According to PMC, Type 1 CNV is the more common CNV subtype, found inabout 67 percentof neovascular AMD eyes in one case series.
Fibrovascular PEDs indicate active wet AMD. Your doctor typically starts anti-VEGF treatment when a fibrovascular PED is identified, especially if subretinal or intraretinal fluid is also present.
Serous PEDs appear as dome-shaped RPE elevations over an optically empty (dark) space on OCT. The space beneath the RPE is filled with clear fluid. According to PMC, the presence of adjacent subretinal fluid or intraretinal fluid near a serous PED implies active CNV that requires treatment.
A serous PED without surrounding fluid may be monitored without treatment in some cases. Your doctor makes this decision based on the PED's size, location relative to the fovea, and whether fluid is present in the retinal layers above.
Hemorrhagic PEDs occur when blood collects between the RPE and Bruch's membrane. On OCT, they appear as large, dome-shaped, bright lesions that block the view of deeper structures. According to PMC, hemorrhagic PEDs carry a poor visual prognosis because blood trapped under the RPE can cause scarring and rapid cell death.
If you have a hemorrhagic PED, your doctor may recommend anti-VEGF injections and, in some cases, additional procedures to displace or remove the trapped blood. Treatment aims to limit scarring and preserve as much vision as possible.
How Your Doctor Monitors Fluid and PEDs
Your doctor uses OCT at every follow-up visit to measure the amount of subretinal fluid, the height and shape of any PED, and the presence of intraretinal fluid (fluid within the retinal layers themselves). These measurements guide treatment decisions.
A decrease in fluid volume after anti-VEGF treatment indicates that the medication is working. Persistent or increasing fluid may prompt your doctor to shorten your injection interval or switch to a different anti-VEGF agent.
Fluorescein angiography reveals the source of fluid leakage by showing where abnormal blood vessels are active. Your doctor injects a yellow dye into a vein in your arm and photographs it as it flows through your retinal blood vessels. Leaking areas glow bright on the images.
This test is especially useful when your doctor needs to determine the type of PED or locate the exact position of CNV. Not every visit requires angiography, but your doctor may order it when OCT findings change.
Your doctor tracks three fluid compartments: subretinal fluid (between retina and RPE), intraretinal fluid (within the retina), and sub-RPE fluid (within a PED). Changes in any compartment can signal disease activity. According to PMC (2024), automated OCT algorithms can now measure fluid volumes precisely, helping your doctor detect small changes between visits.
If all three compartments are dry, your doctor may extend the interval between injections. If new fluid appears, your doctor shortens the interval or adjusts medication. This treat-and-extend approach balances treatment burden with disease control.
Questions About Subretinal Fluid and PEDs in AMD
In the context of AMD, subretinal fluid usually indicates active neovascularization (wet AMD). Other conditions like central serous retinopathy can also cause SRF. Your doctor uses imaging to determine the source. If CNV is present, wet AMD is the diagnosis.
The progression is not a direct conversion. However, eyes with drusenoid PEDs face an increased risk of developing CNV elsewhere in the macula, which would then be classified as a fibrovascular PED. Your doctor monitors drusenoid PEDs for signs of neovascular activity.
When your doctor says your retina is 'dry,' it means OCT shows no subretinal or intraretinal fluid. This is the goal of anti-VEGF treatment. A dry retina indicates that the abnormal vessels are no longer actively leaking. Your doctor may extend your injection interval when your retina stays dry.
A small drusenoid PED in the setting of dry AMD may not require treatment, but it does warrant monitoring. A small PED with any surrounding fluid or a fibrovascular appearance needs anti-VEGF evaluation. Tell your doctor about any new visual symptoms, even if the PED is small.
Blood trapped beneath the RPE (hemorrhagic PED) can cause rapid and severe vision loss. The blood damages RPE cells and photoreceptors through both mechanical pressure and toxic breakdown products. Prompt treatment aims to limit this damage, but some vision loss from hemorrhagic PEDs may be lasting.
Yes. Fluid recurrence is common in wet AMD, which is why ongoing treatment and monitoring are essential. According to PMC, recurrence rates after stopping anti-VEGF therapy range from29 to 58 percentwithin one to two years. Your doctor monitors your OCT at each visit to catch recurrence early.
Talk with Your Doctor About Your Fluid Status
Understanding whether you have subretinal fluid or a PED helps you follow your treatment plan with clarity. Ask your doctor to show you your OCT images and explain what the fluid findings mean for your specific AMD care.